Economic. Spanish Assessment
|
|
- Edwin Harvey
- 6 years ago
- Views:
Transcription
1 IHESA Interstim Health Economic Spanish Assessment Shangai March 2006 ISPOR, 2º Asia- Pacific Congress José-Manuel Rodriguez Barrios BPharm, MPH, MSc, MPhil Health Economics & Reimbursement Manager Medtronic Ibérica 1
2 Study Participants Navarro Albert, and Muñoz Arantxa. Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain Brosa Max. Oblikue Consulting Gisbert Ramon. Economics Department Vic University Rodriguez JM, Serrano-Contreras D. Health Economics & Reimbursement Medtronic Iberia Minda K, Health Economics & Reimbursement Medtronic SARL Tolochenatz Switzerland 2
3 Fecal incontinence Fecal incontinence (FI) can be one of the most psychologically and socially debilitating conditions in an otherwise healthy individual (Nelson, 2004) It can lead to social isolation, loss of self-esteem and self-confidence, and depression Prevalence in Spain has been estimate between 2.2%-15% (Minguez M, 2004) Incidence rates reach 2.2% Spanish general population (Minguez M, 2004) Etiology is not clear and depends on one or a combination of several factors can lead to the inability to control passage of stool or flatus Mínguez M, Benages A. Calidad de vida en los pacientes con incontinencia anal. Gastroenterol Hepatol 2004;27(Supl 3): Nelson RL: Epidemiology of fecal incontinence. Gastroenterology 126:S3-S7,
4 Fecal incontinence. Current management. The goal of treatment for patients with FI is to restore continence and to improve the QoL Specific treatment of fecal incontinence may be considered under the following categories: Treatments: o Non surgical procedures: Dietary advice Pharmacologic therapy Biofeedback therapy o Surgical procedures: Sphincteroplasty Graciloplasty Sacral Nerve Stimulation Colostomía 4
5 Economic model. Objectives MAIN To assess the clinical and economic consequences of adding Interstim in the management of fecal incontinence in Spain. SPECIFIC To build up a decision analytic tool to model the costs and effects (Utilities) associated to two alternative scenarios in the management of fecal incontinence: two therapeutic scheme with and without Interstim. To use the economic model to estimate the expected budget impact of extending/introducing the use of Interstim in Spain. To develop an interactive version of the economic model to provide with a tool useful in the local adaptation of the results. 5
6 Economic model. Methods Type of analysis: retrospective cost-effectiveness using a decision tree model with an attached Markov model to account for mid/long term outcomes The whole model as developed in EXCEL Costs: only medical direct costs are considered Effects: outcomes of comparators are translated into QALYs Data sources: literature review and expert opinion for both clinical and economic parameters Time horizon: 5 years Discount rate: both costs and effects are discounted at a 3% annual rate Point of view: that of the NHS 6
7 Economic model. Comparators The study is divided in two sub analysis for two patient groups SDAS (Structural Deficient Anal sphincter) IAS (Intact Anal Sphincter) For each group of patients a specific model was developed, in which two alternative scenarios are compared: Therapeutic scheme without interstim Therapeutic scheme with interstim In both cases, the analysis begins when conservative treatment has failed to control patients fecal incontinence. 7
8 Treatment algorithm of FI Conservative therapy Success SDAS IAS Success Sphincteroplasty Sacral nerve stimulation Sacral nerve stimulation Artificial anal sphincter / Dynamic graciloplasty Success Success Artificial Anal sphincter / Dynamic graciloplasty Colostomy 8
9 Economic model. Model structure (SDAS) M 9
10 Economic model. Model structure (IAS) IF-IAS M 10
11 Markov Sub model Patients can delay their entrance to Markov model until 2 years (patients in which the firsts 3 treatment fail) For every therapy we have effectiveness rates at long term (5 yrs.) We project the results until 7 years time horizon Markov sub model We have to assume effectiveness rates for the last two years for patients successfully treated at first and second line 11
12 - Jarrett ME, Mowatt G, Glazener CM, Fraser C, Nicholls RJ, Grant AM, Kamm MA: Systematic review of sacral nerve stimulation for faecal incontinence and constipation. Br.J.Surg. 91: , Expert opinion 12
13 Resource Uses Data 13
14 Other parameters 14
15 Cost-effectiveness results (SDAS patients) Patients in the Interstim scenario have a gain around 0,314 SFY at an incremental cost of /SFY. The incremental cost per QUALY in SDAS patients is /QUALY what means that introduction of Interstim in the management of IF in Spain is an efficient therapy SFY: Symptom Free years QALYs: Quality Adjusted Life Years 15
16 Cost-effectiveness results (IAS patients) Patients in the Interstim scenario have a gain around 0,34 SFY at an incremental cost of /SFY. The incremental cost per QUALY in IAS patients is /QUALY what means that introduction of Interstim in the management of IF in Spain is an efficient therapy SFY: Symptom Free years QALYs: Quality Adjusted Life Years 16
17 Cost-effectiveness: Probabilistic analysis SDAS (1.000 simulations) All the simulations showed consistent results 17
18 Cost-effectiveness: Probabilistic analysis IAS (1.000 simulations) All the simulations showed consistent results 18
19 Acceptability curve Assuming the threshold considered as efficient therapy in Spain ( /AVAC ) the figure shows that 97% of the simulations in SDAS an 80% in IAS patients become bellow this rate 19
20 Budget impact main assumptions 20
21 Budget impact results Introducing Interstim in the management of FI can be carried out at a reasonable incremental cost, representing an incremental from 0,7% to 1,8% in the management of FI 21
22 Economic model. Limitations Lack of evidence for effectiveness figures, especially in the long term Main model assumptions are based on expert opinion QALYs are estimated using utility values associated to urinary incontinence patients (published data) Results are very sensitive to different approaches to timehorizon definition 22
23 Economic model. Conclusions Surgical management of FI including Interstim in the therapeutic scheme is a cost-effective option when comparing with Spain Cost-effectiveness threreshold The budget impact analysis show that the introduction of Interstim in the management of FI in the therapeutic scheme in Spain can be performed at a reasonable cost Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. What is an efficient health technology in Spain?. Gac.Sanit. 2002; 16:
24 Methodological issues To describe natural disease history decision tree was selected as the clearest method, but chronic and repetitive IF states requires a Markov approach. PSA was carried out with all parameters ranges from the model. A Monte Carlo Simulation analysis was performed with a 1000 patients cohort to display C-E plane and acceptability curves for SDAS and IAS patients. Beta distribution was used for probabilities and Lognormal distribution for model costs using updated recommendations Micro costing strategy to assign costs for both, the BIA and the Costutility model. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med.Decis.Making 2002; 22: Claxton K, Schupher M, McCabe C, Briggs A, Akehurst R, Buxton M et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005; 14:
How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E
How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E Record Status This is a critical abstract of an economic evaluation that meets
More informationHealth technology The study compared three strategies for diagnosing and treating obstructive sleep apnoea syndrome (OSAS).
Cost-effectiveness of split-night polysomnography and home studies in the evaluation of obstructive sleep apnea syndrome Deutsch P A, Simmons M S, Wallace J M Record Status This is a critical abstract
More informationDuc M. Vo, MD, FACS Northwest Surgical Specialists
Duc M. Vo, MD, FACS Northwest Surgical Specialists Disclosures none Outline Definition Etiologies Exam findings Additional testing Medical management Surgical options What is fecal incontinence? Recurrent
More informationPARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS. A08/S/d Colorectal: Faecal Incontinence (Adult)
A08/S/d 2013/14 NHS STANDARD CONTRACT FOR COLORECTAL: FAECAL INCONTINENCE (ADULT) PARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS Service Specification No. Service Commissioner Lead Provider
More informationClinical Commissioning Policy Statement: Sacral Nerve Stimulation (SNS) for Faecal Incontinence in Adults April Reference: NHSCB/A08/PS/b
Clinical Commissioning Policy Statement: Sacral Nerve Stimulation (SNS) for Faecal Incontinence in Adults April 2013 Reference: NHSCB/A08/PS/b NHS Commissioning Board Clinical Commissioning Policy Statement:
More informationHelicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J
Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment Pohl H, Finlayson S R, Sonnenberg A, Robertson D J Record Status This is a critical abstract of an economic
More informationRandomised Mixed Methods Pilot Trial of Sacral and Percutaneous Tibial Nerve Stimulation for Faecal Incontinence
Research for Patient Benefit Randomised Mixed Methods Pilot Trial of Sacral and Percutaneous Tibial Nerve Stimulation for Faecal Incontinence Thin NN 1, Taylor SJC 2, Bremner SA 2, Hounsome N 2, Alam A
More informationA CASE STUDY OF VALUE OF INFORMATION
A CASE STUDY OF VALUE OF INFORMATION, Research Fellow 1/19 Background The ISPOR good practices for performance-based risk-sharing arrangements task force recommends using value of information analysis
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE The management of faecal incontinence in adults 1.1 Short title Faecal incontinence 2 Background (a) (b) (c) The National Institute
More informationAppendix. Lifetime extrapolation of data from the randomised controlled DiGEM trial
Appendix Lifetime extrapolation of data from the randomised controlled DiGEM trial Judit Simon, Alastair Gray, Philip Clarke, Alisha Wade, Andrew Neil, Andrew Farmer on behalf of the Diabetes Glycaemic
More informationSummary 1. Comparative effectiveness of sapropterin dihydrochloride
Cost-effectiveness of sapropterin dihydrochloride (Kuvan ) for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown
More informationSource of effectiveness data The effectiveness evidence was derived from published studies and from experts' opinions.
Analisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en Espana [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia
More informationCost-effectiveness analysis of different strategies for treating duodenal ulcer Badia X, Segu J L, Olle A, Brosa M, Mones J, Ponte L G
Cost-effectiveness analysis of different strategies for treating duodenal ulcer Badia X, Segu J L, Olle A, Brosa M, Mones J, Ponte L G Record Status This is a critical abstract of an economic evaluation
More informationHealth technology The use of oseltamivir for the treatment of influenza in otherwise healthy children.
Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children Reisinger K, Greene G, Aultman R, Sander B, Gyldmark M Record Status This is a critical abstract
More informationCritical Appraisal Skills. Professor Dyfrig Hughes Health Economist AWMSG
Critical Appraisal Skills Professor Dyfrig Hughes Health Economist AWMSG Critical appraisal of economic evaluations Quality of the underlying evidence Quality of the analysis Quality of reporting 1. Quality
More informationRadiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer Konski A
Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer Konski A Record Status This is a critical abstract of an economic evaluation that meets the
More informationCost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Chan P S, Vijan S, Morady F, Oral H
Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Chan P S, Vijan S, Morady F, Oral H Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationCost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation
Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation January 2013 1. A rapid review submission on the drug ivacaftor
More informationClopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation
More informationCost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V Record Status This is a critical abstract of an economic evaluation that meets
More informationACG Clinical Guideline: Management of Benign Anorectal Disorders
ACG Clinical Guideline: Management of Benign Anorectal Disorders Arnold Wald, MD, MACG 1, Adil E. Bharucha, MBBS, MD 2, Bard C. Cosman, MD, MPH, FASCRS 3 and William E. Whitehead, PhD, MACG 4 1 Division
More informationCost-effectiveness of omalizumab in patients with severe persistent allergic asthma Brown R, Turk F, Dale P, Bousquet J
Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma Brown R, Turk F, Dale P, Bousquet J Record Status This is a critical abstract of an economic evaluation that meets the
More informationStudy population The study population comprised a hypothetical cohort of poorly reversible COPD patients with a history of exacerbations.
Development of an economic model to assess the cost-effectiveness of treatment interventions for chronic obstructive pulmonary disease Spencer M, Briggs A H, Grossman R F, Rance L Record Status This is
More informationDescription. Section: Medicine Effective Date: April 15, 2016 Subsection: Medicine Original Policy Date: June 7, Page: 1 of 6.
Section: Medicine Effective Date: April 15, 2016 Page: 1 of 6 Last Review Status/Date: March 2016 Description Radiofrequency (RF) energy has been investigated as a minimally invasive treatment of fecal
More informationCost-effectiveness of endovascular abdominal aortic aneurysm repair Michaels J A, Drury D, Thomas S M
Cost-effectiveness of endovascular abdominal aortic aneurysm repair Michaels J A, Drury D, Thomas S M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationFaecal Incontinence: Assessment and Management
Mrs PK; 56 yrs; Married; 2 children Faecal Incontinence: Assessment and Management Professor Marc A Gladman MBBS DFFP PhD MRCOG FRCS (UK) FRACS Professor of Colorectal Surgery >10 years of incontinence
More informationThe Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting
The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting April 2013 1. Omacor is a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic
More informationStapled Haemorrhoidopexy NICE review. 1 Executive Summary
1 Executive Summary In the United Kingdom, the most common surgical procedure for the treatment of haemorrhoids is the Milligan-Morgan haemorrhoidectomy. This technique has been subject to numerous modifications
More informationNovel Options for the Management of Fecal Incontinence
Novel Options for the Management of Fecal Incontinence Arnold Wald, MD, MACG University of Wisconsin School of Medicine and Public Health, Madison WI ANORECTAL CONTINENCE MECHANISMS Reservoir Elements
More informationCritical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment
Review For reprint orders, please contact reprints@future-drugs.com Critical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment Marco Barbieri, Michael
More informationCost-Effectiveness of Sacral Neuromodulation Compared to Botulinum Neurotoxin A or Continued Medical Management in Refractory Overactive Bladder
VALUE IN HEALTH 14 (2011) 219 228 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Cost-Effectiveness of Sacral Neuromodulation Compared to Botulinum Neurotoxin A or Continued
More informationLets talk about Faecal incontinence (FI) in Scleroderma
Lets talk about Faecal incontinence (FI) in Scleroderma Dr. Shamaila Butt Gastroenterology Research Registrar GI Physiology unit University College Hospital London GI manifestations in Scleroderma Oesophagus
More informationClinical Policy: Fecal Incontinence Treatments Reference Number: PA.CP.MP.137
Clinical Policy: Fecal Incontinence Treatments Reference Number: PA.CP.MP.137 Effective Date: 01/18 Last Review Date: 12/16 Coding Implications Revision Log Description Fecal incontinence defined as the
More informationA Case of Fecal Incontinence: Medical and Interventional Treatment Options
A Case of Fecal Incontinence: Medical and Interventional Treatment Options HPI JP is a 69 year-old F with a 12-month history of FI. Her symptoms began after a colonoscopy She has been experiencing passive
More informationClinical Commissioning Policy: Sacral Nerve Stimulation (SNS) For Faecal Incontinence In Adults. December Reference : NHSCB/A8/d
Clinical Commissioning Policy: Sacral Nerve Stimulation (SNS) For Faecal Incontinence In Adults December 2012 Reference : NHSCB/A8/d NHS Commissioning Board Clinical Commissioning Policy: Sacral Nerve
More informationSetting The setting was a hospital. The economic study was conducted in the USA.
Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion Brown G C, Brown M M, Sharma S, Busbee B, Brown H Record Status This is a critical abstract of
More information1. Comparative effectiveness of liraglutide
Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding
More informationIs proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? Konski A, Speier W, Hanlon A, Beck J R, Pollack A
Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? Konski A, Speier W, Hanlon A, Beck J R, Pollack A Record Status This is a critical abstract of an economic evaluation
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
A cost-utility analysis of clopidogrel in patients with non-st-segment-elevation acute coronary syndromes in the UK Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R Record
More informationExploring uncertainty in cost effectiveness analysis. Francis Ruiz NICE International (acknowledgements to: Benjarin Santatiwongchai of HITAP)
Exploring uncertainty in cost effectiveness analysis Francis Ruiz NICE International (acknowledgements to: Benjarin Santatiwongchai of HITAP) NICE International and HITAP copyright 2013 Why uncertainty
More informationConservative Management of Functional Bowel & Pelvic Floor Disorders
Conservative Management of Functional Bowel & Pelvic Floor Disorders Kathy Davis PhD BSc(Hons)SRN Specialist Nurse Consultant Parkside Hospital & Minerva Medical Clinic Overview Burden of disease Aims
More informationOHTAC Recommendation
OHTAC Recommendation Sacral Nerve Stimulation for the Management of Urge Incontinence, Urgency-Frequency, Urinary Retention and Fecal Incontinence March 2, 2005 1 The Ontario Health Technology Advisory
More informationA70.4 Insertion of neurostimulator electrodes into peripheral nerve Z12.2 Posterior tibial nerve R15.X Faecal incontinence
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous tibial nerve stimulation (PTNS) for
More informationStudy population The study population comprised a hypothetical cohort of patients with severe sepsis and septic shock.
Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock Neilson A R, Burchardi H, Schneider H Record Status This is a critical abstract
More informationCost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods Yamamoto M, Nakama H
Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods Yamamoto M, Nakama H Record Status This is a critical abstract of an economic
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective Delea T E, Sofrygin
More informationAssessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model
Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Aggarwal R, Ghoshal U C, Naik S R Record Status This is
More informationSetting The setting was secondary care. The economic study was carried out in Canada.
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical
More informationHealth technology The use of tension-free vaginal tape (TVT) for the treatment of female stress urinary incontinence (SUI).
Cost effectiveness of tension-free vaginal tape for the surgical management of female stress incontinence Kilonzo M, Vale L, Stearns S C, Grant A, Cody J, Glazener C M, Wallace S, McCormack K Record Status
More information2/5/2016. ABS Complications. Anal Slings-investigational
ABS Complications Anal Slings-investigational Similar to transvaginal tape or transobturator tape for UI Dacron, mersilene, polyester, and teflon mesh, fascia lata Wound infections, sinus tract, t ulcer
More informationORIGINAL ARTICLE. Quality of Life and Morbidity After Permanent Sacral Nerve Stimulation for Fecal Incontinence
ORIGINAL ARTICLE Quality of Life and Morbidity After Permanent Sacral Nerve Stimulation for Fecal Incontinence Franc H. Hetzer, MD; Dieter Hahnloser, MD; Pierre-Alain Clavien, MD, PhD; Nicolas Demartines,
More informationNICE Guidelines for HTA Issues of Controversy
NICE Guidelines for HTA Issues of Controversy Mark Sculpher, PhD Professor of Health Economics University of York, UK LMI, Medicines Agency in Norway and the Norwegian Knowledge Centre for the Health Services:
More informationIs noncontact normothermic wound therapy cost effective for the treatment of stages 3 and 4 pressure ulcers Macario A, Dexter F
Is noncontact normothermic wound therapy cost effective for the treatment of stages 3 and 4 pressure ulcers Macario A, Dexter F Record Status This is a critical abstract of an economic evaluation that
More informationCost-effectiveness analysis of screening for celiac disease in the adult population Shamir R, Hernell O, Leshno M
Cost-effectiveness analysis of screening for celiac disease in the adult population Shamir R, Hernell O, Leshno M Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationSetting The setting was primary care. The economic study was carried out in the USA.
Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Schousboe J T, Ensrud K E, Nyman J A, Melton L J,
More informationSelection of aortic valve replacement versus transcatheter aortic valve replacement in high-risk patients: a Markov model
Selection of aortic valve replacement versus transcatheter aortic valve replacement in high-risk patients: a Markov model Hemal Gada, MD, MBA and Thomas H Marwick, MD, PhD Department of Cardiovascular
More informationScreening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K
Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K Record Status This is a critical abstract of an economic evaluation that meets the
More informationThe Augmented Representation of the Cost-effectiveness Acceptability Curve for Economic Evaluation of Health Technology
Kobe J. Med. Sci., Vol. 61, No. 1, pp. E9-E18, 2015 The Augmented Representation of the Cost-effectiveness Acceptability Curve for Economic Evaluation of Health Technology DAIJI ARAKI 1, 1, 2, 3 * and
More informationOutcomes assessed in the review The outcomes assessed in the review and used as model inputs were the incident rates of:
The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes Scuffham P, Carr L Record Status This is a critical abstract of
More informationQuantitative benefit-risk assessment: An analytical framework for a shared understanding of the effects of medicines. Patrick Ryan 21 April 2010
Quantitative benefit-risk assessment: An analytical framework for a shared understanding of the effects of medicines Patrick Ryan 21 April 2010 Challenges in understanding the effects of medicines Benefit
More informationThe cost-utility of screening for depression in primary care Valenstein M, Vijan S, Zeber J E, Boehm K, Buttar A
The cost-utility of screening for depression in primary care Valenstein M, Vijan S, Zeber J E, Boehm K, Buttar A Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationLinezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H
Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H Record Status This is a critical abstract of an economic evaluation
More informationGI Physiology - Investigating and treating patients with pelvic floor dysfunction. Lynne Smith Department of GI Physiology NGH Sheffield
GI Physiology - Investigating and treating patients with pelvic floor dysfunction Lynne Smith Department of GI Physiology NGH Sheffield Aims o o o To give an overview of lower GI investigations To demonstrate
More informationDecision Analysis. John M. Inadomi. Decision trees. Background. Key points Decision analysis is used to compare competing
5 Decision Analysis John M. Inadomi Key points Decision analysis is used to compare competing strategies of management under conditions of uncertainty. Various methods may be employed to construct a decision
More informationCan Universal Screening for rare conditions ever be cost-effective? The case of Newborn Screening for Biliary Atresia
Can Universal Screening for rare conditions ever be cost-effective? The case of Newborn Screening for Biliary Atresia Lisa Masucci 1, Stirling Bryan 1, Janusz A. Kaczorowski 3, Jean-Paul Collet 2, Richard
More informationFECAL INCONTINENCE. John H. Winston, III, M.D., M.B.A.
FECAL INCONTINENCE John H. Winston, III, M.D., M.B.A. Diplomate, American Board of Colon & Rectal Surgery Diplomate, American Board of Surgery www.colorectalsurgeryservices.com Fecal Incontinence (FI)
More informationACCIDENTAL BOWEL LEAKAGE: A PRACTICAL APPROACH TO EVALUATION. Tristi W. Muir, MD Chair, Department of OB/GYN Houston Methodist Hospital
ACCIDENTAL BOWEL LEAKAGE: A PRACTICAL APPROACH TO EVALUATION Tristi W. Muir, MD Chair, Department of OB/GYN Houston Methodist Hospital Accidental Bowel Leakage What Gets the Woman into Your Office 67%
More informationSecukinumab for treating moderate to severe plaque psoriasis. Erratum
Aberdeen HTA Group Secukinumab for treating moderate to severe plaque psoriasis Erratum Completed 2 March 2015 This report was commissioned by the NIHR HTA Programme as project number 13/129/01 Contains
More informationAdvanced Decision Analysis: Markov Models
Advanced Decision Analysis: Markov Models Reasons to understand Markov models It s the standard in academia Very powerful/flexible tool simple decision trees relatively inflexible limited time frame hard
More informationStudy population The study population comprised type 1 and 2 diabetic patients without renal complications.
Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines van Os N, Niessen L W, Bilo H J, Casparie A F, van Hout B A Record Status This is a critical abstract
More informationSepsis. National Clinical Guideline Centre. Sepsis: the recognition, diagnosis and management of sepsis. NICE guideline <number> January 2016
National Clinical Guideline Centre Consultation Sepsis Sepsis: the recognition, diagnosis and management of sepsis NICE guideline Appendices I-O January 2016 Draft for consultation Commissioned
More informationTransanal Radiofrequency Treatment of Fecal Incontinence
Medical Policy Manual Surgery, Policy No. 129 Transanal Radiofrequency Treatment of Fecal Incontinence Next Review: December 2018 Last Review: December 2017 Effective: February 1, 2018 IMPORTANT REMINDER
More informationSection A: Clarification on effectiveness data. Licensed population
Section A: Clarification on effectiveness data Licensed population A1: priority question Please provide the information depicted in the following table for each of the subgroups listed below (i.e., 7 tables
More informationClinical Policy Title: Injectable bulking agents for fecal incontinence
Clinical Policy Title: Injectable bulking agents for fecal incontinence Clinical policy number: 08.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date: June
More informationUse of gatekeeper in obese patients with fecal incontinence before bariatric surgery, is it improving the results?
International Surgery Journal Ibrahim AAM. Int Surg J. 2017 Nov;4(11):3594-3598 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20174876
More informationCost-effectiveness of intraoperative facial nerve monitoring in middle ear or mastoid surgery Wilson L, Lin E, Lalwani A
Cost-effectiveness of intraoperative facial nerve monitoring in middle ear or mastoid surgery Wilson L, Lin E, Lalwani A Record Status This is a critical abstract of an economic evaluation that meets the
More informationCost-effectiveness of apremilast (Otezla )
Cost-effectiveness of apremilast (Otezla ) alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs) for the treatment of active psoriatic arthritis in adult patients who have had an
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationThe cost of the Axonics sacral neuromodulation system is 475 for the trial phase, 9,210 for a
pat hways Axonics sacral al neuromodulation system for overactive bladder and faecal incontinence Medtech innovation briefing Published: 10 December 2018 nice.org.uk/guidance/mib164 Summary The technology
More informationTransanal Radiofrequency Treatment of Fecal Incontinence
2.01.58 Transanal Radiofrequency Treatment of Fecal Incontinence Section 2.0 Medicine Effective Date January 30, 2015 Subsection Original Policy Date July 6, 2012 Next Review Date January 2016 Description
More informationFaecal Incontinence Information Leaflet THE DIGESTIVE SYSTEM
THE DIGESTIVE SYSTEM This factsheet is about faecal incontinence Faecal (or anal) incontinence is the loss of stool, liquid or gas from the bowel at an undesirable time. Males and females of any age may
More information2/5/2016. Evolving Surgical Treatment Approaches for Fecal Incontinence in Women: An Evidence and Cased-Based Approach
Evolving Surgical Treatment Approaches for Fecal Incontinence in Women: An Evidence and Cased-Based Approach Holly E Richter, PhD, MD, FACOG, FACS J Marion Sims Professor Obstetrics and Gynecology Professor
More informationCost-utility of initial medical management for Crohn's disease perianal fistulae Arseneau K O, Cohn S M, Cominelli F, Connors A F
Cost-utility of initial medical management for Crohn's disease perianal fistulae Arseneau K O, Cohn S M, Cominelli F, Connors A F Record Status This is a critical abstract of an economic evaluation that
More informationReal-world observational data in costeffectiveness analyses: Herceptin as a case study
Real-world observational data in costeffectiveness analyses: Herceptin as a case study DR BONNY PARKINSON, PROFESSOR ROSALIE VINEY, ASSOCIATE PROFESSOR STEPHEN GOODALL AND PROFESSOR MARION HAAS ISPOR AUSTRALIA
More informationCost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationEconomics of tandem mass spectrometry screening of neonatal inherited disorders Pandor A, Eastham J, Chilcott J, Paisley S, Beverley C
Economics of tandem mass spectrometry screening of neonatal inherited disorders Pandor A, Eastham J, Chilcott J, Paisley S, Beverley C Record Status This is a critical abstract of an economic evaluation
More informationFaecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U
Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U Record Status This is a critical abstract of an economic evaluation
More informationSuspected cancer: National Collaborating Centre for Cancer. recognition and management of suspected cancer in children, young people and adults
National Collaborating Centre for Cancer : recognition and management of suspected cancer in children, young people and adults Clinical Guideline Appendices A - E June 2015 Final version Commissioned by
More informationAbout the National Centre for Pharmacoeconomics
Cost-effectiveness of mannitol dry powder for inhalation (Bronchitol ) for the treatment of adult patients with cystic fibrosis as an add-on therapy to best standard of care. The NCPE has issued a recommendation
More informationTechnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471
Eluxadoline for treating irritable bowel syndrome with diarrhoea Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 NICE 2017. All rights reserved. Subject to Notice of
More informationSetting The setting was primary care. The economic study was carried out in Norway.
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program Wisloff T, Abrahamsen T G, Bergsaker M A, Lovoll O, Moller P, Pedersen M K, Kristiansen
More informationSetting The setting was unclear. The economic study was conducted in Switzerland.
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Roze S, Valentine W J, Zakrzewska K E, Palmer A J Record
More informationCONTENT OVERVIEW. 1. Introduction 2. Objectives 3. Methods 4. Results 5. Conclusions
September 2017 COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE U100 IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES FROM THE PERSPECTIVE OF THE SPANISH NATIONAL HEALTHCARE SYSTEM:
More informationSetting The setting was the community. The economic study was carried out in the USA.
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis Yun H R, Bae S C Record
More informationEvidence based assessment of the value of innovation: pricing solutions and prospects
Evidence based assessment of the value of innovation: pricing solutions and prospects Karl Claxton 7/11/2017 How much can we pay for innovation? Cost Price > P* 60,000 30,000 per QALY Cost-effectiveness
More informationCost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy
Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy The NCPE has issued a recommendation regarding the cost-effectiveness
More information